ArticleJournal of clinical and diagnostic research : JCDR2014
Promoter hypermethylation profile of tumour suppressor genes in oral leukoplakia and oral squamous cell carcinoma.
Article in Journal of clinical and diagnostic research : JCDR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis.Medicine · 2018Pooled it
- Assessment of Promoter Hypermethylation in Tumor Suppressor Genes in Oral Leukoplakia and Oral Submucous Fibrosis.Journal of pharmacy & bioallied sciences · 2025Article
- Molecular insight into histone methylation as a novel target for oral squamous cell carcinoma: future hope in personalised medicine.Journal of Cancer · 2025Review
- Deep sequencing of candidate genes identified 14 variants associated with smoking abstinence in an ethnically diverse sample.Scientific reports · 2024Article
- Article
- Genome-wide DNA methylation profiling of HPV-negative leukoplakia and gingivobuccal complex cancers.Clinical epigenetics · 2023Article
- Improving the Diagnostic Performance by Adding Methylation Marker to Conventional Visual Examination in Identifying Oral Cancer.Diagnostics (Basel, Switzerland) · 2022Article
- An Unanticipated Modulation of Cyclin-Dependent Kinase Inhibitors: The Role of Long Non-Coding RNAs.Cells · 2022Review
- An Overview of DNA Methylation Indicators for the Course of Oral Precancer.Applied bionics and biomechanics · 2022Review
- Saliva Gene Promoter Hypermethylation as a Biomarker in Oral Cancer.Journal of clinical medicine · 2021Review
- Targeted therapies for non-HPV-related head and neck cancer: challenges and opportunities in the context of predictive, preventive, and personalized medicine.The EPMA journal · 2019Review
- Epigenetic silencing of ZNF132 mediated by methylation-sensitive Sp1 binding promotes cancer progression in esophageal squamous cell carcinoma.Cell death & disease · 2018Article
- Leveraging Genomics for Head and Neck Cancer Treatment.Journal of dental research · 2018Review
- Aberrant DNA methylation of theJournal of Cancer · 2018Article
- High-risk oral leukoplakia is associated with aberrant promoter methylation of multiple genes.BMC cancer · 2016Article
- Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer.EBioMedicine · 2016Review
- DNA methylation markers for oral pre-cancer progression: A critical review.Oral oncology · 2016Review
- The association, clinicopathological significance, and diagnostic value ofOncoTargets and therapy · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the studyThe present study was conducted to evaluate epigenetic alteration of five tumour suppressor genes in the oral precancer and cancer patients. MATERIALS AND
methodsThe study was carried out in three groups namely control group of five people (normal healthy individuals), 10 oral leukoplakia patients and 10 oral squamous cell carcinoma patients. Incisional biopsy was done and part of the tissue sent for histological examination and part of tissue sent for hypermethylation study of p16, p15, hMLH, MGMT, E-cadherin tumour suppressor genes. Methylation specific polymerase chain reaction was carried out for detecting methylation in promoter regions of tumour suppressor genes. The resultant PCR products were run in a 2.5% agarose gel and the promoter hypermethylation status of the five tumour suppressor genes were analysed.
resultsIn oral Leukoplakia patients, 60% of methylation in the case of p16 gene, 30% of methylation in the case of MGMT gene and 60% of methylation in the case of E-cadherin gene. In oral Squamous cell carcinoma patients, 60% of methylation in the case of p16 gene, 40% of methylation in the case of MGMT, 60% of methylation in the case of E-cadherin gene, 20% in case of p15,10% in case of hMLH gene.
conclusionOur results suggest that epigenetic mechanisms of inactivation of tumour suppressor genes, such as aberrant methylation of p16 and E-cadherin genes occur early in head and neck tumourigenesis and might play a role in the progression of these lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.